1-2 of 2
Christine J. Pak
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy

Free
Xinqi Wu, Anita Giobbie-Hurder, Xiaoyun Liao, Courtney Connelly, Erin M. Connolly, Jingjing Li, Michael P. Manos, Donald Lawrence, David McDermott, Mariano Severgnini, Jun Zhou, Evisa Gjini, Ana Lako, Mikel Lipschitz, Christine J. Pak, Sara Abdelrahman, Scott Rodig, F. Stephen Hodi
Journal: Cancer Immunology Research
Cancer Immunol Res (2017) 5 (1): 17–28.
https://doi.org/10.1158/2326-6066.CIR-16-0206
Published: 03 January 2017
View articletitled, Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
Open the PDF for Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy in another window
Includes: Supplementary data
Journal Articles

Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status

Free
Margaretha G.M. Roemer, Ranjana H. Advani, Robert A. Redd, Geraldine S. Pinkus, Yasodha Natkunam, Azra H. Ligon, Courtney F. Connelly, Christine J. Pak, Christopher D. Carey, Sarah E. Daadi, Bjoern Chapuy, Daphne de Jong, Richard T. Hoppe, Donna S. Neuberg, Margaret A. Shipp, Scott J. Rodig
Journal: Cancer Immunology Research
Cancer Immunol Res (2016) 4 (11): 910–916.
https://doi.org/10.1158/2326-6066.CIR-16-0201
Published: 31 October 2016
View articletitled, Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status
Open the PDF for Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status in another window
Includes: Supplementary data